We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
-5.46%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.3K
AUM Growth
-$34.2M
Cap. Flow
+$12.8M
Cap. Flow %
13,125.97%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ALNA
Allena Pharmaceuticals
ALNA
+$12.8M

Top Sells

Rank Stock Value
1
ARGS
Argos Therapeutics, Inc.
ARGS
+$16.7K

Sector Composition

Rank Sector Weight
1 Healthcare 84.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGS
1
DELISTED
Argos Therapeutics, Inc.
ARGS
$39.4K 40.54%
657,139
-4,975
-0.8% -$16.7K
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.71B
$20.4K 21.01%
982,270
– –
ARGS
3
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$15.4K 15.79%
256,030
– –
ALNA
4
DELISTED
Allena Pharmaceuticals
ALNA
$10.4K 10.73%
+1,037,267
New +$12.8M
JNCE
5
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$8.44K 8.68%
662,063
– –
TARA icon
6
Protara Therapeutics
TARA
$229M
$3.17K 3.26%
41,698
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q4 2017 Portfolio in Review

As of Q4 2017, Pharmstandard International held 6 positions worth $97.3K, down 100% from $34.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pharmstandard International deployed $12.8M of net new capital in Q4 2017, opening 1 new position. Its largest new stake was Allena Pharmaceuticals: 1,037,267 shares worth $10.4K.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Argos Therapeutics, Inc., an estimated $16.7K trimmed.

  • Pharmstandard International's largest Q4 2017 buy was Allena Pharmaceuticals: 1,037,267 shares worth $10.4K.
  • Pharmstandard International's biggest Q4 2017 reduction was Argos Therapeutics, Inc., cutting an estimated $16.7K.
  • Pharmstandard International's ten largest holdings make up 100% of its $97.3K portfolio in Q4 2017.
  • Pharmstandard International opened 1 new position and closed 0 in Q4 2017.
  • Pharmstandard International's portfolio value fell 100% quarter-over-quarter to $97.3K.

Based on Pharmstandard International's 13F filing for Q4 2017, filed 14 Feb 2018.